sarilumab high dose (400mg) - versus control - for COVID-19 pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.86 [0.46, 1.60]< 10%2 studies (2/-)68.3 %highnot evaluable lowcrucial-
clinical improvement 2.09 [1.00, 4.36]> 10%1 study (1/-)97.5 %highnot evaluable lowimportant-
death or ventilation 0.39 [0.18, 0.82]< 10%1 study (1/-)99.4 %highnot evaluable lowimportant-
mechanical ventilation 0.27 [0.10, 0.71]< 10%1 study (1/-)99.6 %highnot evaluable lowimportant-
off oxygenation 1.99 [0.95, 4.15]> 10%1 study (1/-)96.7 %highnot evaluable lownon important-

safety endpoints 00

serious adverse events 1.38 [0.76, 2.51]< 10%1 study (1/-)14.6 %some concernnot evaluable moderateimportant-
adverse events 1.31 [0.76, 2.27]< 10%1 study (1/-)16.6 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.